Takeaway

• Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) vs other glucose-lowering drugs in routine clinical practice is associated with decreased risk for hospitalization for heart failure (HHF), all-cause death, myocardial infarction (MI), and stroke across 13 countries on 3 continents.

Why this matters

• Most randomized clinical trials of new type 2 diabetes (T2D) drugs...